The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.
stem cell transplantation
Although some advances have been made in first-line and salvage treatment, epithelial ovarian carcinoma remains a leading cause of gynecological cancer deaths. [1] [2] [3] Numerous studies have focused on dose intensification, based on the in vivo observation that there is a dose-response correlation for certain tumors. Modest nonmyeloablative dose increases have been evaluated in a randomized manner with the general conclusion that this approach is unlikely to yield a survival advantage. 4 A much higher dose intensity can be achieved with hematopoietic stem cell support and this technology has greatly evolved over the past decade. The use of peripheral blood as the source of hematopoietic progenitors along with improvement in supportive care has reduced transplant mortality and morbidity. Progress has also been made in the understanding that not all patients are likely to benefit from such an approach. To try to further elucidate this point, we have looked at 96 patients treated with high-dose chemotherapy and autologous stem cell transplantation. We have analyzed patient and disease characteristics along with transplant regimens, with the objective of defining survival and disease-free survival in different clinical settings.
Patients and methods

Patients
Between February 1994 and June 2000, 96 patients with epithelial ovarian cancer received high-dose chemotherapy with peripheral blood stem cell transplantation. Patients provided written informed consent in accordance with our institutional review board. Patients' demographics and tumor characteristics are summarized in Table 1 .
Patients were eligible for transplantation if they were physiological age p60 years, had histologically proven invasive epithelial ovarian cancer stage III-IV in first clinical CR, clinically persistent or progressive disease with initial induction chemotherapy or if they had recurrent disease. Patients with fallopian tube or primary peritoneal carcinoma were also treated. Patients had to have undergone prior tumor reductive surgery, total abdominal hysterectomy, bilateral salpingo-oophorectomy and staging laparotomy.
Other criteria for transplantation included: an estimated creatinine clearance greater than 50 or 60 ml/min depending on the regimen, adequate liver function with an ALT, AST and bilirubin less than twice the upper normal limit; normal cardiac ejection fraction; pulmonary diffusion capacity greater than 50% of predicted; and platelet count greater than 100 Â 10 9 /l. Relapsed patients were considered platinum-refractory or resistant if they had failed to achieve at least a partial remission to a platinum-containing regimen or had relapsed within 6 months of completing a platinum-containing regimen.
Treatment plan
Blood stem cell mobilization and collection. For peripheral blood stem cell mobilization and collection, 17 patients received cyclophosphamide 4 g/m 2 by intravenous infusion over 2 h. Mesna 1 g/m 2 was given intravenously over 30 min prior to the cyclophosphamide and 3 g/m 2 was given by continuous infusion over 24 h after the cyclophosphamide. In all, 12 patients received cyclophosphamide 3 g/m 2 by intravenous infusion with mesna as previously described (day 1) and paclitaxel 200 mg/m 2 by intravenous infusion over 3 h (day 1). A total of 67 patients received ifosfamide 3.33 g/m 2 /day administered by continuous infusion over 24 h for three doses (days 1-3), and etoposide 150 mg/m 2 administered intravenously over 2 h every 12 h for six doses (days 1-3). Mesna was given at 2 g/m 2 by intravenous infusion before and at the completion of the ifosfamide. Mesna was also given at a total dose of 8 g/m 2 by continuous infusion concomitantly with the ifosfamide infusion. All patients received filgrastim 5-6 mg/kg rounded to the nearest vial size (300 or 480 mg), subcutaneously twice per day until completion of stem cell collection. Details of the mobilization and collection of these patients have been previously described. 5 High-dose chemotherapy regimens. Patients received one of three high-dose chemotherapy regimens. In all, 24 patients received a regimen of four cycles of high-dose paclitaxel with carboplatin (PC). The first 12 patients were on a dose escalation study, three patients were treated at one of four dose levels and the remainder were treated at the maximum tolerated dose, which is the highest dose described below. Paclitaxel at a dose of 175-250 mg/m 2 was administered on day À3 as a single 24 h intravenous infusion after premedication with dexamethasone 20 mg orally given 14 and 7 h prior, and cimetidine 300 mg intravenously and diphenhydramine 50 mg intravenously both given 1 h prior. At the completion of the paclitaxel, carboplatin was administered at a dose determined by the Calvert equation. 6 The desired AUC ranged from 10 to 16.6. This combination was administered monthly for a total of four cycles.
In all, 73 patients received the high-dose combination of topotecan, melphalan and cyclophosphamide (TMC). Of these patients, 53 were treated as part of a topotecan dose escalating study and have been previously reported. 7 The other 15 patients were treated at the described maximal tolerated dose, which is 4 mg/m 2 /day. Cyclophosphamide 1 g/m 2 /day was given intravenously over 2 h on days À6, À5, À4; melphalan 70 mg/m 2 /day was given intravenously over 30 min on days À3 and À2. Both agents were administered immediately before the topotecan. Topotecan was given intravenously over 30 min daily for five total doses on days À6 to À2. The topotecan dose ranged from 1.25 to 4 mg/m 2 /day. Five patients received a combination of high-dose cyclophosphamide, carmustine and thiotepa (CBT). Cyclophosphamide 2 g/m 2 /day was given intravenously over 2 h on days À7, À6, À5 with mesna 500 mg/m 2 intravenously 30 min before the first dose, than 2 g/m 2 /day by continuous infusion for 3 days. Carmustine 150 mg/m 2 /day was given intravenously over 2 h on days À7, À6 and À5. Thiotepa 240 mg/m 2 was given intravenously over 4 h on days À7, À6 and À5. For all regimens, peripheral blood hematopoietic stem cells were infused on day 0.
Supportive care. All patients received filgrastim 5 mg/kg/ day rounded to the nearest vial size, subcutaneously from day 0 until the absolute neutrophil count reached at least 1.5 Â 10 9 /l. Prophylactic antibiotics with ciprofloxacin, noroxin or levaquin, fluconazole, acyclovir or valacyclovir were given. Transfusion of blood products was administered to maintain a hemoglobin level above 8.0 g/dl and platelets above 15 Â 10 9 /l.
Definition of relapse and response
Patients had disease evaluation within 30 days prior to enrollment, 30 days after transplantation and every 3 months for the following 2 years. Evaluation was carried out with a complete physical examination, CT scan or MRI of the abdomen and pelvis and serum CA-125. After the second year, patients were evaluated every 4 months with a physical examination and a CA-125. Patients were considered to have measurable disease if they had a tumor that could be measured in two dimensions by imaging studies or physical examination. Patients were considered to have evaluable disease if they had no measurable disease on scans or physical examination but had an elevated serum CA-125 level (435 U/ml) in two samples. For patients with measurable disease, a complete response was defined as the complete disappearance of clinical evidence of tumor and a normalization of the serum CA-125 level. A partial response was defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measurable disease and, if elevated, a 50% or greater decrease or normalization of the CA-125 level. For patients Median number of prior regimens 2 (range [1] [2] [3] [4] [5] [6] with evaluable disease only, response was determined by using the CA-125 serum levels as described by Rustin et al:
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(1) A 50% response is considered to have occurred if there is a 50% decrease in CA-125 serum levels. There must be two initial samples, and the sample showing the 50% decrease must be confirmed by a fourth sample. (2) A 75% response is considered to have occurred if there has been a decrease in serum CA-125 levels of more than 75% over three samples. For establishing disease progression, elevation of the CA-125 above 35 U/ml measured on two separate occasions was considered an independent indicator of relapse. Patients with a previously elevated CA-125 level as a disease marker and who presented with a new abnormality on their CT scan or physical examination required a biopsy to confirm the relapse only if their CA-125 level was within the normal range. Patients who never presented with an elevated CA-125 as a disease marker were considered to have relapsed if a new lesion clinically consistent with recurrence was detected radiologically or on physical examination without requiring a biopsy.
Statistical analysis
Analysis of progression-free survival (PFS) and overall survival was carried out from the time of registration, which was immediately prior to the start of the mobilization or high-dose chemotherapy. All surviving patients were followed up to October 2000, with the exception of one patient, who was lost to follow-up 18 months post transplantation. The median follow-up among surviving patients is 18 months (range: 3.5-68). The cumulative proportion for survival and PFS was estimated by the Kaplan-Meier method. Prognostic factors for survival and PFS at median follow-up were evaluated on univariate analysis using the log rank test. Statistical significance was determined at the 0.05 level. The analysis was performed using STATA 7.0 (STATA Corporation, College Station, TX, USA).
Results
Patients
A total of 96 patients were treated and a total of 102 transplantations were performed. Six patients received two transplant regimens, five patients who had previously received high-dose cyclophosphamide, carmustine, thiotepa, and one patient who had received paclitaxel and carboplatin went on to the topotecan, melphalan, cyclophosphamide regimen for treatment of persistent or recurrent disease. Follow-up since the first transplant was considered in this analysis (N ¼ 96), except for the comparison of outcomes according to the preparative regimen where data from both transplants were included (N ¼ 102). The pretransplant characteristics of patients treated with each preparative regimen are summarized in Tables 2 and 3 . The median number of prior chemotherapy regimens was 2 (range: 1-6). The median age was 49 years (range: 22-67). In total, 71 patients (74%) were platinumsensitive, and 25 (26%) were platinum-refractory or resistant.
Survival and PFS
There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38% (95% CI 15-60) with a PFS of 13% (95% CI 4-25). For the 41 patients who received transplantation for remission consolidation, the 6-year survival was 53% (95% CI 18-79) with a PFS of 29% (95% CI 10-50). The survival and PFS is shown in Figures  1 and 2 .
Prognostic factors for survival and PFS
Histology, tumor grade, response prior to transplantation, transplant regimen, platinum-sensitivity, age, initial stage and tumor debulking were analyzed. The results are summarized in Table 4 . The disease status prior to transplantation was the most significant prognostic factor for both overall survival (Figure 3 ) and PFS. As expected, this factor was highly correlated with platinum sensitivity (all patients in clinical CR were platinumsensitive), which was also associated with improved overall survival and PFS. The CBT regimen was associated with a significantly worse survival, and there was a trend for better survival beyond 18 months for TMC compared to the paclitaxel and carboplatin combination Table 2 Percentage of patients with platinum-sensitive or platinum-resistant/refractory disease in each treatment group (24) 5% (4) 16% (12) 15% (11) 12% ( ( Figure 4 ). The clear cell histology did significantly worse than all other histologies for both survival and PFS. Since four of the five patients receiving the CBT regimen and all the patients with clear cell histology were not in a clinical CR at the time of transplantation, a multivariate analysis to account for the independent effect of each factor could not be made. However, when excluding the CBT regimen and clear cell histology, disease status before transplantation remained the only significant predictor of PFS (P ¼ 0.01). Similarly, the CBT regimen and clear cell histology remained significant adverse factors for both survival and PFS (Po0.05) when restricting the analysis to patients not in clinical CR at the time of transplantation. This suggests that these three factors, CBT regimen, clear cell histology and clinical CR at the time of transplantation, affect prognosis independently. Owing to the high correlation between diseases status and platinum-sensitivity, the independent effect of these factors could not be evaluated in a multivariate analysis. Platinum sensitivity, however, had no significant impact on survival or PFSs for patients not in clinical CR at the time of transplantation.
Discussion
In this analysis, we have again demonstrated that patients with low volume disease are more likely to benefit from high-dose treatment. We have also observed that there are differences in efficacy for different transplant regimens, and that clear cell histology is a significant adverse prognostic factor. Figure 3 Overall survival by response prior to transplantation.
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Clear cell ovarian carcinoma has been previously described as a subset of epithelial ovarian carcinomas presenting with somewhat unique clinical features. Although some controversy still exists, most specifically for endometriosis-associated clear cell carcinomas, it is usually recognized that these patients have an overall worse prognosis in the context of standard therapy.
9-12 Although we only treated a small number of patients with this histology, based on our analysis it is unlikely that patients with clear cell ovarian carcinoma will benefit from intensive chemotherapy regimens such as the ones described here. The Autologous Blood and Marrow Transplant Registry also reported on the unfavorable prognosis of clear cell histology. 13 This analysis demonstrates that transplantation may be most beneficial for remission consolidation. Another approach with somewhat more limited data has been radiation therapy. In a study by MacGibbon et al, 16 51 patients with o2 cm of residual disease at the time of second-look surgery were treated with whole abdominal radiotherapy. The median dose delivered was 2244 cGY in a median of 22 fractions; 86% of patients also received a pelvic boost. The 5-year survival was 27%. Other studies have shown 5-year survivals in the ranges of 40-49% for patients consolidated with whole abdominal radiotherapy. 17, 18 A commonly used consolidation method in clinical practice is standard-dose chemotherapy continued beyond remission. There have been trials comparing shorter vs longer chemotherapy treatments; overall, there is little scientific evidence that prolonging standard induction chemotherapy offers a survival advantage. 19, 20 Newer approaches have included IP interferon-alpha, which has shown activity in patients with low volume chemosensitive disease. 21 Clinical trials are underway to determine the role of other therapies, including interleukins and gene therapy. 22 High-dose chemotherapy has been studied in the consolidation setting. Recently, the European Blood and Marrow Transplant (EBMT) Registry reported on 254 patients with ovarian carcinoma treated with hematopoietic transplantation. The patients treated in remission had a median overall survival of 32 months. Patients with stage III disease transplanted in first complete or partial remission had a median survival of 59 months. 23 The French study by Legros et al 24 reported a median survival of 66 months in a similar consolidation group treated after second-look surgery.
The availability of only phase II data makes it difficult to conclude that one of these approaches to consolidation therapy is superior. Our series, which includes patients in first and in greater than first remission, had a 6-year overall survival and PFS of 53 and 29%. This appears to be at least equal to other consolidation strategies. A concern with high-dose treatment has been the mortality risk and quality-of-life issues. Current high-dose chemotherapy treatments have very low mortality risks (0% in this cohort) and with single intensification regimens, the therapy is usually completed in under 2 months. Quality of life trials will be necessary to assess patients undergoing transplantation consolidation, compared to other therapies.
This analysis has also demonstrated that the TMC regimen may be superior to the paclitaxel/carboplatin combination and is superior to the cyclophosphamide/ carmustine and thiotepa regimen. Previous comparisons of different transplant regimens had failed to demonstrate the superiority of a single combination. 24, 25 It is possible that using non-cross-resistant drugs for consolidation of mostly platinum-treated patients is the preferable approach. The importance of combining drugs that have significant singleagent activity is also demonstrated by our results. Longer follow-up will be needed to confirm the advantage of TMC in our series.
Numerous strategies have been studied for remission consolidation of ovarian carcinoma. Fairly extensive phase II data are available for the use of high-dose chemotherapy in this setting. However, because of patient selection biases, it is impossible to compare reliably these different modalities. Since there is no standard or clearly superior treatment of patients in clinical remission, continued participation in clinical trials is recommended. Phase III trials of high-dose chemotherapy in patients with low volume disease are currently underway. 
